PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies) - Global Forecast to 2021
The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, and increase in adoption of protein based drugs over non-protein based drugs. In addition, rising opportunities in emerging markets, and top-selling biologics drugs going off-patent in the near future provides a growing opportunity to this market.
This report segments the global PEGylated proteins market by product, protein type, application and end-user. By product, the market includes consumables and services. Based on protein type, the market is segmented into colony stimulating factors, interferons, erythropoietin, mAbs, and recombinant factor VIII. The colony stimulating factors segment will hold the largest share of the PEGylated proteins type market in 2016.
The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share in the global the PEGylated proteins market in 2016. Asia is expected to register the fastest growth in the forecast period.
Research Coverage:
This report studies the PEGylated proteins market based on product, protein type, application, and end-user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions
Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and to help them make important strategic growth decisions.
The report provides insights on the following:
This report segments the global PEGylated proteins market by product, protein type, application and end-user. By product, the market includes consumables and services. Based on protein type, the market is segmented into colony stimulating factors, interferons, erythropoietin, mAbs, and recombinant factor VIII. The colony stimulating factors segment will hold the largest share of the PEGylated proteins type market in 2016.
The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share in the global the PEGylated proteins market in 2016. Asia is expected to register the fastest growth in the forecast period.
Research Coverage:
This report studies the PEGylated proteins market based on product, protein type, application, and end-user. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions
Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and to help them make important strategic growth decisions.
The report provides insights on the following:
- Product Development/Innovation: Product portfolios of the top players in the PEGylated proteins market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the insights on upcoming technologies market
- Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the PEGylated proteins market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various PEGylated proteins across geographies
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the PEGylated proteins market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
2.3.1 KEY DATA FROM SECONDARY SOURCES
2.3.2 KEY DATA FROM PRIMARY SOURCES
2.3.3 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION
4 PREMIUM INSIGHTS
4.1 PEGYLATED PROTEINS: MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: PEGYLATED PROTEINS MARKET, BY END USER
4.3 PEGYLATED PROTEINS MARKET: GEOGRAPHIC SNAPSHOT
4.4 LIFE CYCLE ANALYSIS, BY REGION (2016)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.1.1 DRIVERS
5.1.1.1 Increase in R&D spending
5.1.1.2 Growth in the biologics sector
5.1.1.3 Increase in adoption of protein-based drugs
5.1.1.4 Use of PEGylation to increase protein stability and peptide half-life
5.1.1.5 High prevalence of lifestyle diseases
5.1.2 RESTRAINTS
5.1.2.1 Drug failures and recalls
5.1.3 OPPORTUNITIES
5.1.3.1 Opportunities in emerging markets
5.1.3.2 Patient expiry of top-selling biologics
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 PORTER’S FIVE FORCES ANALYSIS
6.2.1 THREAT FROM NEW ENTRANTS
6.2.2 THREAT OF SUBSTITUTES
6.2.3 BARGAINING POWER OF SUPPLIERS
6.2.4 BARGAINING POWER OF BUYERS
6.2.5 INTENSITY OF COMPETITIVE RIVALRY
6.3 REGULATORY SCENARIO
6.4 PIPELINE ANALYSIS
7 PEGYLATED PROTEINS MARKET, BY PRODUCTS AND SERVICES
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 PEGYLATION REAGENTS
7.2.1.1 Monofunctional Linear PEGs
7.2.1.2 Bifunctional PEGs
7.2.1.3 Multi-arm PEGs
7.2.1.4 Branched PEGs
7.2.1.5 Other PEGylation Reagents
7.2.2 PEGYLATION KITS
7.3 SERVICES
7.3.1 DEVELOPMENT OF PEGYLATED BIOSIMILARS
7.3.2 PROCESS DEVELOPMENT OF PEG-DRUG CONJUGATE MANUFACTURING
7.3.3 PILOT PRODUCTION OF PEG-DRUG CONJUGATE
7.3.4 ANALYTICAL METHOD DEVELOPMENT
7.3.5 PEGYLATION FEASIBILITY STUDIES
8 PEGYLATED PROTEINS MARKET, BY TYPE
8.1 INTRODUCTION
8.2 COLONY-STIMULATING FACTORS
8.3 INTERFERONS
8.4 ERYTHROPOIETIN (EPO)
8.5 MONOCLONAL ANTIBODIES
8.6 RECOMBINANT FACTOR VIII
8.7 OTHER PROTEIN TYPES
9 PEGYLATED PROTEINS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 CANCER
9.3 HEPATITIS
9.4 CHRONIC KIDNEY DISEASE
9.5 HEMOPHILIA
9.6 MULTIPLE SCLEROSIS
9.7 GASTROINTESTINAL DISORDERS
9.8 OTHER APPLICATIONS
10 PEGYLATED PROTEINS MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.4 ACADEMIC RESEARCH INSTITUTES
11 PEGYLATED PROTEINS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.3 EUROPE
11.4 ASIA
11.5 REST OF THE WORLD
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 STRATEGIC ANALYSIS
12.3 MARKET SHARE ANALYSIS
12.4 STRATEGIC BENCHMARKING
12.4.1 AGREEMENTS & COLLABORATIONS
12.5 COMPETITIVE SITUATION AND TRENDS
12.5.1 AGREEMENTS & COLLABORATIONS
12.5.2 PRODUCT LAUNCHES AND PRODUCT SHOWCASE
12.5.3 ACQUISITIONS
12.5.4 PRODUCT UPGRADES
13 COMPANY PROFILES
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 INTRODUCTION
13.2 MERCK MILLIPORE
13.3 THERMO FISHER SCIENTIFIC INC.
13.4 NOF AMERICAN CORPORATION (A SUBSIDIARY OF NOF CORPORATION)
13.5 JENKEM TECHNOLOGY CO., LTD.
13.6 CREATIVE PEGWORKS
13.7 CELARES GMBH
13.8 QUANTA BIODESIGN, LTD.
13.9 BIOMATRIK, INC.
13.10 IRIS BIOTECH GMBH
13.11 LAYSAN BIO, INC.
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.5 AVAILABLE CUSTOMIZATIONS
14.6 RELATED REPORTS
14.7 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
2.3.1 KEY DATA FROM SECONDARY SOURCES
2.3.2 KEY DATA FROM PRIMARY SOURCES
2.3.3 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION
4 PREMIUM INSIGHTS
4.1 PEGYLATED PROTEINS: MARKET OVERVIEW
4.2 GEOGRAPHIC ANALYSIS: PEGYLATED PROTEINS MARKET, BY END USER
4.3 PEGYLATED PROTEINS MARKET: GEOGRAPHIC SNAPSHOT
4.4 LIFE CYCLE ANALYSIS, BY REGION (2016)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.1.1 DRIVERS
5.1.1.1 Increase in R&D spending
5.1.1.2 Growth in the biologics sector
5.1.1.3 Increase in adoption of protein-based drugs
5.1.1.4 Use of PEGylation to increase protein stability and peptide half-life
5.1.1.5 High prevalence of lifestyle diseases
5.1.2 RESTRAINTS
5.1.2.1 Drug failures and recalls
5.1.3 OPPORTUNITIES
5.1.3.1 Opportunities in emerging markets
5.1.3.2 Patient expiry of top-selling biologics
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 PORTER’S FIVE FORCES ANALYSIS
6.2.1 THREAT FROM NEW ENTRANTS
6.2.2 THREAT OF SUBSTITUTES
6.2.3 BARGAINING POWER OF SUPPLIERS
6.2.4 BARGAINING POWER OF BUYERS
6.2.5 INTENSITY OF COMPETITIVE RIVALRY
6.3 REGULATORY SCENARIO
6.4 PIPELINE ANALYSIS
7 PEGYLATED PROTEINS MARKET, BY PRODUCTS AND SERVICES
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 PEGYLATION REAGENTS
7.2.1.1 Monofunctional Linear PEGs
7.2.1.2 Bifunctional PEGs
7.2.1.3 Multi-arm PEGs
7.2.1.4 Branched PEGs
7.2.1.5 Other PEGylation Reagents
7.2.2 PEGYLATION KITS
7.3 SERVICES
7.3.1 DEVELOPMENT OF PEGYLATED BIOSIMILARS
7.3.2 PROCESS DEVELOPMENT OF PEG-DRUG CONJUGATE MANUFACTURING
7.3.3 PILOT PRODUCTION OF PEG-DRUG CONJUGATE
7.3.4 ANALYTICAL METHOD DEVELOPMENT
7.3.5 PEGYLATION FEASIBILITY STUDIES
8 PEGYLATED PROTEINS MARKET, BY TYPE
8.1 INTRODUCTION
8.2 COLONY-STIMULATING FACTORS
8.3 INTERFERONS
8.4 ERYTHROPOIETIN (EPO)
8.5 MONOCLONAL ANTIBODIES
8.6 RECOMBINANT FACTOR VIII
8.7 OTHER PROTEIN TYPES
9 PEGYLATED PROTEINS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 CANCER
9.3 HEPATITIS
9.4 CHRONIC KIDNEY DISEASE
9.5 HEMOPHILIA
9.6 MULTIPLE SCLEROSIS
9.7 GASTROINTESTINAL DISORDERS
9.8 OTHER APPLICATIONS
10 PEGYLATED PROTEINS MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3 CONTRACT RESEARCH ORGANIZATIONS
10.4 ACADEMIC RESEARCH INSTITUTES
11 PEGYLATED PROTEINS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.3 EUROPE
11.4 ASIA
11.5 REST OF THE WORLD
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 STRATEGIC ANALYSIS
12.3 MARKET SHARE ANALYSIS
12.4 STRATEGIC BENCHMARKING
12.4.1 AGREEMENTS & COLLABORATIONS
12.5 COMPETITIVE SITUATION AND TRENDS
12.5.1 AGREEMENTS & COLLABORATIONS
12.5.2 PRODUCT LAUNCHES AND PRODUCT SHOWCASE
12.5.3 ACQUISITIONS
12.5.4 PRODUCT UPGRADES
13 COMPANY PROFILES
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 INTRODUCTION
13.2 MERCK MILLIPORE
13.3 THERMO FISHER SCIENTIFIC INC.
13.4 NOF AMERICAN CORPORATION (A SUBSIDIARY OF NOF CORPORATION)
13.5 JENKEM TECHNOLOGY CO., LTD.
13.6 CREATIVE PEGWORKS
13.7 CELARES GMBH
13.8 QUANTA BIODESIGN, LTD.
13.9 BIOMATRIK, INC.
13.10 IRIS BIOTECH GMBH
13.11 LAYSAN BIO, INC.
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.5 AVAILABLE CUSTOMIZATIONS
14.6 RELATED REPORTS
14.7 AUTHOR DETAILS
LIST OF TABLES
Table 1 PEGYLATED PROTEINS MARKET SUMMARY
Table 2 FDA-APPROVED PEGYLATED DRUGS IN THE MARKET (1990–2014)
Table 3 PEGYLATED DRUGS IN PIPELINE
Table 4 PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT AND SERVICE, 2014–2021 (USD MILLION)
Table 5 PEGYLATED PROTEINS MARKET SIZE FOR CONSUMABLES, BY TYPE, 2014–2021 (USD MILLION)
Table 6 PEGYLATED PROTEINS MARKET SIZE FOR CONSUMABLES, BY REGION, 2014–2021 (USD MILLION)
Table 7 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CONSUMABLES, BY REGION, 2014–2021 (USD MILLION)
Table 8 PEGYLATION REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 9 NORTH AMERICA: PEGYLATION KITS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 10 PEGYLATION KITS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 11 NORTH AMERICA: PEGYLATION KITS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 12 PEGYLATED PROTEIN MARKET SIZE FOR SERVICES, BY TYPE, 2014–2021 (USD MILLION)
Table 13 PEGYLATED PROTEINS MARKET SIZE FOR SERVICES, BY REGION, 2014–2021 (USD MILLION)
Table 14 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR SERVICES, BY REGION, 2014–2021 (USD MILLION)
Table 15 PEGYLATED PROTEINS MARKET SIZE FOR DEVELOPMENT OF PEGYLATED BIOSIMILARS, BY REGION, 2014–2021 (USD MILLION)
Table 16 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR DEVELOPMENT OF PEGYLATED BIOSIMILARS, BY REGION, 2014–2021 (USD MILLION)
Table 17 PEGYLATED PROTEINS MARKET SIZE FOR PROCESS DEVELOPMENT OF PEG-CONJUGATE MANUFACTURING, BY REGION, 2014–2021 (USD MILLION)
Table 18 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PROCESS DEVELOPMENT OF PEG-CONJUGATE MANUFACTURING, BY REGION, 2014–2021 (USD MILLION)
Table 19 PEGYLATED PROTEINS MARKET SIZE FOR PILOT PRODUCTION OF PEG-DRUG CONJUGATE, BY REGION, 2014–2021 (USD MILLION)
Table 20 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PILOT PRODUCTION OF PEG-DRUG CONJUGATE, BY REGION, 2014–2021 (USD MILLION)
Table 21 PEGYLATED PROTEINS MARKET SIZE FOR ANALYTICAL METHOD DEVELOPMENT, BY REGION, 2014–2021 (USD MILLION)
Table 22 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR ANALYTICAL METHOD DEVELOPMENT, BY REGION, 2014–2021 (USD MILLION)
Table 23 PEGYLATED PROTEINS MARKET SIZE FOR PEGYLATION FEASIBILITY STUDIES, BY REGION, 2014–2021 (USD MILLION)
Table 24 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PEGYLATION FEASIBILITY STUDIES, BY REGION, 2014–2021 (USD MILLION)
Table 25 PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 26 PEGYLATED PROTEINS MARKET SIZE FOR COLONY-STIMULATING FACTORS, BY REGION, 2014–2021 (USD MILLION)
Table 27 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 28 PEGYLATED PROTEINS MARKET SIZE FOR INTERFERONS, BY REGION, 2014–2021 (USD MILLION)
Table 29 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR INTERFERONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 30 PEGYLATED PROTEINS MARKET SIZE FOR ERYTHROPOIETIN, BY REGION, 2014–2021 (USD MILLION)
Table 31 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR ERYTHROPOIETIN, BY COUNTRY, 2014–2021 (USD MILLION)
Table 32 PEGYLATED PROTEINS MARKET SIZE FOR MONOCLONAL ANTIBODIES, BY REGION, 2014–2021 (USD MILLION)
Table 33 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2014–2021 (USD MILLION)
Table 34 PEGYLATED PROTEINS MARKET SIZE FOR RECOMBINANT FACTOR VIII, BY REGION, 2014–2021 (USD MILLION)
Table 35 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR RECOMBINANT FACTOR VIII, BY COUNTRY, 2014–2021 (USD MILLION)
Table 36 OTHER PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 37 NORTH AMERICA: OTHER PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 38 PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 39 PEGYLATED PROTEINS MARKET SIZE FOR CANCER, BY REGION, 2014–2021 (USD MILLION)
Table 40 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CANCER, BY COUNTRY, 2014–2021 (USD MILLION)
Table 41 PEGYLATED PROTEINS MARKET SIZE FOR HEPATITIS, BY REGION, 2014–2021 (USD MILLION)
Table 42 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR HEPATITIS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 43 PEGYLATED PROTEINS MARKET SIZE FOR CHRONIC KIDNEY DISEASE, BY REGION, 2014–2021 (USD MILLION)
Table 44 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CHRONIC KIDNEY DISEASE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 45 PEGYLATED PROTEINS MARKET SIZE FOR HEMOPHILIA, BY REGION, 2014–2021 (USD MILLION)
Table 46 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR HEMOPHILIA, BY COUNTRY, 2014–2021 (USD MILLION)
Table 47 PEGYLATED PROTEINS MARKET SIZE FOR MULTIPLE SCLEROSIS, BY REGION, 2014–2021 (USD MILLION)
Table 48 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 49 PEGYLATED PROTEINS MARKET SIZE FOR GASTROINTESTINAL DISORDERS, BY REGION, 2014–2021 (USD MILLION)
Table 50 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 51 PEGYLATED PROTEINS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014–2021 (USD MILLION)
Table 52 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 53 PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 54 PEGYLATED PROTEINS MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2014–2021 (USD MILLION)
Table 55 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2014–2021 (USD MILLION)
Table 56 PEGYLATED PROTEINS MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014–2021 (USD MILLION)
Table 57 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 58 PEGYLATED PROTEINS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2014–2021 (USD MILLION)
Table 59 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2014–2021 (USD MILLION)
Table 60 PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 61 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 62 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 63 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 64 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 65 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 66 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 67 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 68 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 69 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 70 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 71 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 72 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 73 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 74 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 75 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 76 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 77 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 78 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 79 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 80 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 81 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 82 ROW: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 83 ROW: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 84 ROW: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 85 ROW: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 86 MARKET DEVELOPMENTS BETWEEN 2013 AND 2016
Table 87 AGREEMENTS & COLLABORATIONS, 2013–2016
Table 88 PRODUCT LAUNCHES AND PRODUCT SHOWCASE, 2013–2016
Table 89 ACQUISITIONS, 2013–2016
Table 90 PRODUCT UPGRADES, 2013–2016
Table 1 PEGYLATED PROTEINS MARKET SUMMARY
Table 2 FDA-APPROVED PEGYLATED DRUGS IN THE MARKET (1990–2014)
Table 3 PEGYLATED DRUGS IN PIPELINE
Table 4 PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT AND SERVICE, 2014–2021 (USD MILLION)
Table 5 PEGYLATED PROTEINS MARKET SIZE FOR CONSUMABLES, BY TYPE, 2014–2021 (USD MILLION)
Table 6 PEGYLATED PROTEINS MARKET SIZE FOR CONSUMABLES, BY REGION, 2014–2021 (USD MILLION)
Table 7 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CONSUMABLES, BY REGION, 2014–2021 (USD MILLION)
Table 8 PEGYLATION REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 9 NORTH AMERICA: PEGYLATION KITS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 10 PEGYLATION KITS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 11 NORTH AMERICA: PEGYLATION KITS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 12 PEGYLATED PROTEIN MARKET SIZE FOR SERVICES, BY TYPE, 2014–2021 (USD MILLION)
Table 13 PEGYLATED PROTEINS MARKET SIZE FOR SERVICES, BY REGION, 2014–2021 (USD MILLION)
Table 14 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR SERVICES, BY REGION, 2014–2021 (USD MILLION)
Table 15 PEGYLATED PROTEINS MARKET SIZE FOR DEVELOPMENT OF PEGYLATED BIOSIMILARS, BY REGION, 2014–2021 (USD MILLION)
Table 16 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR DEVELOPMENT OF PEGYLATED BIOSIMILARS, BY REGION, 2014–2021 (USD MILLION)
Table 17 PEGYLATED PROTEINS MARKET SIZE FOR PROCESS DEVELOPMENT OF PEG-CONJUGATE MANUFACTURING, BY REGION, 2014–2021 (USD MILLION)
Table 18 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PROCESS DEVELOPMENT OF PEG-CONJUGATE MANUFACTURING, BY REGION, 2014–2021 (USD MILLION)
Table 19 PEGYLATED PROTEINS MARKET SIZE FOR PILOT PRODUCTION OF PEG-DRUG CONJUGATE, BY REGION, 2014–2021 (USD MILLION)
Table 20 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PILOT PRODUCTION OF PEG-DRUG CONJUGATE, BY REGION, 2014–2021 (USD MILLION)
Table 21 PEGYLATED PROTEINS MARKET SIZE FOR ANALYTICAL METHOD DEVELOPMENT, BY REGION, 2014–2021 (USD MILLION)
Table 22 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR ANALYTICAL METHOD DEVELOPMENT, BY REGION, 2014–2021 (USD MILLION)
Table 23 PEGYLATED PROTEINS MARKET SIZE FOR PEGYLATION FEASIBILITY STUDIES, BY REGION, 2014–2021 (USD MILLION)
Table 24 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PEGYLATION FEASIBILITY STUDIES, BY REGION, 2014–2021 (USD MILLION)
Table 25 PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 26 PEGYLATED PROTEINS MARKET SIZE FOR COLONY-STIMULATING FACTORS, BY REGION, 2014–2021 (USD MILLION)
Table 27 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 28 PEGYLATED PROTEINS MARKET SIZE FOR INTERFERONS, BY REGION, 2014–2021 (USD MILLION)
Table 29 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR INTERFERONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 30 PEGYLATED PROTEINS MARKET SIZE FOR ERYTHROPOIETIN, BY REGION, 2014–2021 (USD MILLION)
Table 31 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR ERYTHROPOIETIN, BY COUNTRY, 2014–2021 (USD MILLION)
Table 32 PEGYLATED PROTEINS MARKET SIZE FOR MONOCLONAL ANTIBODIES, BY REGION, 2014–2021 (USD MILLION)
Table 33 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2014–2021 (USD MILLION)
Table 34 PEGYLATED PROTEINS MARKET SIZE FOR RECOMBINANT FACTOR VIII, BY REGION, 2014–2021 (USD MILLION)
Table 35 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR RECOMBINANT FACTOR VIII, BY COUNTRY, 2014–2021 (USD MILLION)
Table 36 OTHER PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 37 NORTH AMERICA: OTHER PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 38 PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 39 PEGYLATED PROTEINS MARKET SIZE FOR CANCER, BY REGION, 2014–2021 (USD MILLION)
Table 40 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CANCER, BY COUNTRY, 2014–2021 (USD MILLION)
Table 41 PEGYLATED PROTEINS MARKET SIZE FOR HEPATITIS, BY REGION, 2014–2021 (USD MILLION)
Table 42 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR HEPATITIS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 43 PEGYLATED PROTEINS MARKET SIZE FOR CHRONIC KIDNEY DISEASE, BY REGION, 2014–2021 (USD MILLION)
Table 44 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CHRONIC KIDNEY DISEASE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 45 PEGYLATED PROTEINS MARKET SIZE FOR HEMOPHILIA, BY REGION, 2014–2021 (USD MILLION)
Table 46 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR HEMOPHILIA, BY COUNTRY, 2014–2021 (USD MILLION)
Table 47 PEGYLATED PROTEINS MARKET SIZE FOR MULTIPLE SCLEROSIS, BY REGION, 2014–2021 (USD MILLION)
Table 48 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 49 PEGYLATED PROTEINS MARKET SIZE FOR GASTROINTESTINAL DISORDERS, BY REGION, 2014–2021 (USD MILLION)
Table 50 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 51 PEGYLATED PROTEINS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014–2021 (USD MILLION)
Table 52 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 53 PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 54 PEGYLATED PROTEINS MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2014–2021 (USD MILLION)
Table 55 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2014–2021 (USD MILLION)
Table 56 PEGYLATED PROTEINS MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014–2021 (USD MILLION)
Table 57 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2014–2021 (USD MILLION)
Table 58 PEGYLATED PROTEINS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2014–2021 (USD MILLION)
Table 59 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2014–2021 (USD MILLION)
Table 60 PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 61 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)
Table 62 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 63 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 64 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 65 NORTH AMERICA: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 66 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 67 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 68 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 69 U.S.: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 70 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 71 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 72 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 73 CANADA: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 74 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 75 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 76 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 77 EUROPE: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 78 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 79 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 80 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 81 ASIA: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 82 ROW: PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2014–2021 (USD MILLION)
Table 83 ROW: PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 84 ROW: PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 85 ROW: PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 86 MARKET DEVELOPMENTS BETWEEN 2013 AND 2016
Table 87 AGREEMENTS & COLLABORATIONS, 2013–2016
Table 88 PRODUCT LAUNCHES AND PRODUCT SHOWCASE, 2013–2016
Table 89 ACQUISITIONS, 2013–2016
Table 90 PRODUCT UPGRADES, 2013–2016
LIST OF FIGURES
Figure 1 PEGYLATED PROTEINS MARKET
Figure 2 RESEARCH DESIGN
Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2016 VS. 2021 (USD MILLION)
Figure 8 PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION)
Figure 9 PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
Figure 10 PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
Figure 11 PEGYLATED PROTEINS MARKET: GEOGRAPHIC SNAPSHOT
Figure 12 PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)
Figure 13 INCREASE IN R&D SPENDING TO DRIVE GROWTH IN THE PEGYLATED PROTEINS MARKET
Figure 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND THE LARGEST MARKET SHARE IN 2016
Figure 15 NORTH AMERICA TO REGISTER THE SECOND HIGHEST GROWTH RATE IN THE FORECAST PERIOD
Figure 16 ASIA HOLDS LUCRATIVE GROWTH OPPORTUNITIES IN THE PEGYLATED PROTEINS MARKET
Figure 17 DRUG FAILURES AND RECALLS RESTRAINT THE GROWTH OF THE MARKET
Figure 18 PATENTS FILED, BY REGION, 2014
Figure 19 PORTER’S FIVE FORCES ANALYSIS (2016)
Figure 20 CONSUMABLES SEGMENT COMMANDS THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN 2016
Figure 21 PEGYLATION REAGENTS SEGMENT TO COMMAND THE LARGEST SHARE OF THE CONSUMABLES MARKET IN 2016
Figure 22 PEGYLATION REAGENTS MARKET, BY TYPE
Figure 23 DEVELOPMENT OF PEGYLATED BIOSIMILARS HOLDS THE LARGEST SHARE OF THE SERVICES MARKET IN 2016
Figure 24 COLONY-STIMULATING FACTORS TO DOMINATE THE PEGYLATED PROTEINS MARKET IN 2016
Figure 25 CANCER TREATMENT TO COMMAND THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET, BY APPLICATION, IN 2016
Figure 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO COMMAND THE LARGEST SHARE OF THE PEGYLATED PROTEINS END-USER MARKET IN 2016
Figure 27 PEGYLATED PROTEINS MARKET, BY REGION: 2016 VS. 2021
Figure 28 ASIAN MARKET FOR PEGYLATED PROTEINS EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 29 NORTH AMERICA: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 30 U.S. TO DOMINATE THE PEGYLATED PROTEINS MARKET IN NORTH AMERICA
Figure 31 CONSUMABLES TO FORM THE LARGEST PRODUCT SEGMENT IN THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 32 COLONY-STIMULATING FACTORS TO DOMINATE THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 33 CANCER FORMS THE LARGEST APPLICATION SEGMENT IN THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 34 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND THE LARGEST SHARE IN THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 35 CONSUMABLES TO FORM THE LARGEST PRODUCT SEGMENT IN THE U.S. PEGYLATED PROTEINS MARKET
Figure 36 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE U.S. PEGYLATED PROTEINS MARKET
Figure 37 CANCER TO FORM THE LARGEST APPLICATION SEGMENT IN THE U.S. PEGYLATED PROTEINS MARKET
Figure 38 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE U.S. PEGYLATED PROTEINS MARKET
Figure 39 CONSUMABLES TO FORM THE LARGEST PRODUCT SEGMENT IN THE CANADIAN PEGYLATED PROTEINS MARKET
Figure 40 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE CANADIAN PEGYLATED PROTEINS MARKET
Figure 41 CANCER TO FORM THE LARGEST APPLICATION SEGMENT IN THE CANADIAN PEGYLATED PROTEINS MARKET
Figure 42 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE CANADIAN MARKET PEGYLATED PROTEINS MARKET
Figure 43 EUROPE: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 44 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN EUROPE
Figure 45 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE EUROPEAN PEGYLATED PROTEINS TYPE MARKET
Figure 46 CANCER TREATMENT SEGMENT TO DOMINATE THE APPLICATIONS MARKET IN EUROPE
Figure 47 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE THE END-USER MARKET IN EUROPE
Figure 48 ASIA: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 49 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN ASIA
Figure 50 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE ASIAN PEGYLATED PROTEINS TYPE MARKET
Figure 51 CANCER TREATMENT SEGMENT TO DOMINATE THE APPLICATIONS MARKET IN ASIA
Figure 52 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE THE END-USER MARKET IN ASIA
Figure 53 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN ROW
Figure 54 ROW: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 55 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE ROW PEGYLATED PROTEINS TYPE MARKET
Figure 56 CANCER TREATMENT SEGMENT TO DOMINATE THE APPLICATIONS MARKET IN ROW
Figure 57 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE THE END-USER MARKET IN ROW
Figure 58 KEY DEVELOPMENTS IN THE PEGYLATED PROTEINS MARKET, 2013–2016
Figure 59 PEGYLATED PROTEINS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
Figure 60 STRATEGIES ADOPTED BY MARKET LEADERS BETWEEN 2013–2016
Figure 61 GEOGRAPHIC REVENUE MIX OF THE TOP 3 PLAYERS IN THE PEGYLATED PROTEINS MARKET
Figure 62 COMPANY SNAPSHOT: MERCK MILLIPORE
Figure 63 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC.
Figure 64 COMPANY SNAPSHOT: NOF CORPORATION
Figure 1 PEGYLATED PROTEINS MARKET
Figure 2 RESEARCH DESIGN
Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 PEGYLATED PROTEINS MARKET SIZE, BY PRODUCT & SERVICE, 2016 VS. 2021 (USD MILLION)
Figure 8 PEGYLATED PROTEINS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION)
Figure 9 PEGYLATED PROTEINS MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
Figure 10 PEGYLATED PROTEINS MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
Figure 11 PEGYLATED PROTEINS MARKET: GEOGRAPHIC SNAPSHOT
Figure 12 PEGYLATED PROTEINS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)
Figure 13 INCREASE IN R&D SPENDING TO DRIVE GROWTH IN THE PEGYLATED PROTEINS MARKET
Figure 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND THE LARGEST MARKET SHARE IN 2016
Figure 15 NORTH AMERICA TO REGISTER THE SECOND HIGHEST GROWTH RATE IN THE FORECAST PERIOD
Figure 16 ASIA HOLDS LUCRATIVE GROWTH OPPORTUNITIES IN THE PEGYLATED PROTEINS MARKET
Figure 17 DRUG FAILURES AND RECALLS RESTRAINT THE GROWTH OF THE MARKET
Figure 18 PATENTS FILED, BY REGION, 2014
Figure 19 PORTER’S FIVE FORCES ANALYSIS (2016)
Figure 20 CONSUMABLES SEGMENT COMMANDS THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN 2016
Figure 21 PEGYLATION REAGENTS SEGMENT TO COMMAND THE LARGEST SHARE OF THE CONSUMABLES MARKET IN 2016
Figure 22 PEGYLATION REAGENTS MARKET, BY TYPE
Figure 23 DEVELOPMENT OF PEGYLATED BIOSIMILARS HOLDS THE LARGEST SHARE OF THE SERVICES MARKET IN 2016
Figure 24 COLONY-STIMULATING FACTORS TO DOMINATE THE PEGYLATED PROTEINS MARKET IN 2016
Figure 25 CANCER TREATMENT TO COMMAND THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET, BY APPLICATION, IN 2016
Figure 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO COMMAND THE LARGEST SHARE OF THE PEGYLATED PROTEINS END-USER MARKET IN 2016
Figure 27 PEGYLATED PROTEINS MARKET, BY REGION: 2016 VS. 2021
Figure 28 ASIAN MARKET FOR PEGYLATED PROTEINS EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 29 NORTH AMERICA: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 30 U.S. TO DOMINATE THE PEGYLATED PROTEINS MARKET IN NORTH AMERICA
Figure 31 CONSUMABLES TO FORM THE LARGEST PRODUCT SEGMENT IN THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 32 COLONY-STIMULATING FACTORS TO DOMINATE THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 33 CANCER FORMS THE LARGEST APPLICATION SEGMENT IN THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 34 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND THE LARGEST SHARE IN THE NORTH AMERICAN PEGYLATED PROTEINS MARKET
Figure 35 CONSUMABLES TO FORM THE LARGEST PRODUCT SEGMENT IN THE U.S. PEGYLATED PROTEINS MARKET
Figure 36 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE U.S. PEGYLATED PROTEINS MARKET
Figure 37 CANCER TO FORM THE LARGEST APPLICATION SEGMENT IN THE U.S. PEGYLATED PROTEINS MARKET
Figure 38 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE U.S. PEGYLATED PROTEINS MARKET
Figure 39 CONSUMABLES TO FORM THE LARGEST PRODUCT SEGMENT IN THE CANADIAN PEGYLATED PROTEINS MARKET
Figure 40 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE CANADIAN PEGYLATED PROTEINS MARKET
Figure 41 CANCER TO FORM THE LARGEST APPLICATION SEGMENT IN THE CANADIAN PEGYLATED PROTEINS MARKET
Figure 42 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE CANADIAN MARKET PEGYLATED PROTEINS MARKET
Figure 43 EUROPE: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 44 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN EUROPE
Figure 45 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE EUROPEAN PEGYLATED PROTEINS TYPE MARKET
Figure 46 CANCER TREATMENT SEGMENT TO DOMINATE THE APPLICATIONS MARKET IN EUROPE
Figure 47 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE THE END-USER MARKET IN EUROPE
Figure 48 ASIA: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 49 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN ASIA
Figure 50 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE ASIAN PEGYLATED PROTEINS TYPE MARKET
Figure 51 CANCER TREATMENT SEGMENT TO DOMINATE THE APPLICATIONS MARKET IN ASIA
Figure 52 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE THE END-USER MARKET IN ASIA
Figure 53 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE PEGYLATED PROTEINS MARKET IN ROW
Figure 54 ROW: PEGYLATED PROTEINS MARKET SNAPSHOT
Figure 55 COLONY-STIMULATING FACTORS SEGMENT TO DOMINATE THE ROW PEGYLATED PROTEINS TYPE MARKET
Figure 56 CANCER TREATMENT SEGMENT TO DOMINATE THE APPLICATIONS MARKET IN ROW
Figure 57 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE THE END-USER MARKET IN ROW
Figure 58 KEY DEVELOPMENTS IN THE PEGYLATED PROTEINS MARKET, 2013–2016
Figure 59 PEGYLATED PROTEINS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
Figure 60 STRATEGIES ADOPTED BY MARKET LEADERS BETWEEN 2013–2016
Figure 61 GEOGRAPHIC REVENUE MIX OF THE TOP 3 PLAYERS IN THE PEGYLATED PROTEINS MARKET
Figure 62 COMPANY SNAPSHOT: MERCK MILLIPORE
Figure 63 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC.
Figure 64 COMPANY SNAPSHOT: NOF CORPORATION
